faropenem

Significant reduction in serum valproic acid levels, leading to loss of seizure control or worsening of psychiatric symptoms.

Concomitant use is generally contraindicated. If co-administration is unavoidable, consider alternative antiepileptics or closely monitor valproic acid levels and clinical response, with potential for significant dose adjustments. Alternative antibiotics should be considered.

Significant reduction in serum valproic acid levels, leading to loss of seizure control or worsening of psychiatric symptoms.

Concomitant use is generally contraindicated. If co-administration is unavoidable, consider alternative antiepileptics or closely monitor valproic acid levels and clinical response, with potential for significant dose adjustments. Alternative antibiotics should be considered.

Increased systemic exposure to faropenem, potentially leading to an increased risk of dose-related adverse effects (e.g., gastrointestinal disturbances, CNS effects like seizures at very high concentrations).

Monitor for increased adverse effects of faropenem. Dose adjustment of faropenem may be necessary, especially in patients with renal impairment or if adverse effects occur. This interaction can sometimes be exploited to enhance faropenem's efficacy, but caution is advised.

Increased risk of carbapenem-related adverse effects (e.g., seizures, gastrointestinal disturbances) without additional therapeutic benefit.

Avoid concomitant use. If a carbapenem is indicated, choose one agent. There is no clinical rationale for using two carbapenems simultaneously.

Increased risk of carbapenem-related adverse effects (e.g., seizures, gastrointestinal disturbances) without additional therapeutic benefit.

Avoid concomitant use. If a carbapenem is indicated, choose one agent. There is no clinical rationale for using two carbapenems simultaneously.

Increased risk of carbapenem-related adverse effects (e.g., seizures, gastrointestinal disturbances) without additional therapeutic benefit.

Avoid concomitant use. If a carbapenem is indicated, choose one agent. There is no clinical rationale for using two carbapenems simultaneously.

Increased risk of carbapenem-related adverse effects (e.g., seizures, gastrointestinal disturbances) without additional therapeutic benefit.

Avoid concomitant use. If a carbapenem is indicated, choose one agent. There is no clinical rationale for using two carbapenems simultaneously.

Potential for reduced efficacy of hormonal contraceptives, leading to unintended pregnancy.

Advise patients to use an additional, reliable non-hormonal method of contraception during faropenem treatment and for 7 days after stopping the antibiotic. This interaction is generally considered low risk for most antibiotics, but caution is prudent.

Potential for increased INR and bleeding risk.

Monitor INR more frequently, especially at the start and end of faropenem therapy. Adjust warfarin dose as needed. Advise patients to report any signs of bleeding.